Prof Geoffrey Lindeman
Geoff Lindeman is Joint Head of the Stem Cells and Cancer Division at the Walter and Eliza Hall Institute. He is also a medical oncologist and Director of the Joint Peter Mac and Royal Melbourne Hospital Familial Cancer Centre in the Victorian Comprehensive Cancer Centre. He holds an honorary appointment as Professorial Fellow in the Department of Medicine, University of Melbourne. His laboratory is studying normal mammary gland development as a strategy to identify novel therapeutic targets in breast cancer. By determining how breast stem cells give rise to mature epithelial cells in the breast, it should be possible to decipher the molecular and cellular events that lead to breast cancer. This work has led to the recent discovery of RANK-positive progenitors as a target for breast cancer prevention in BRCA1 mutation carriers. His laboratory is also using patient derived xenograft (PDX) models to test promising anti-cancer agents. This work has led to an early phase study of venetoclax (a BCL-2 inhibitor) in breast cancer.